APHEXDA
PeakPeptidemotixafortide
NDASUBCUTANEOUSPOWDER
Approved
Sep 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
6
Data completeness
5/8 — Partial
APHEXDA (motixafortide) is c-x-c motif chemokine receptor 4 (cxcr4) and blocks the binding of its cognate ligand, stromal-derived factor-1α (sdf-1α)/c-x-c motif chemokine ligand 12 (cxcl12). First approved in 2023.
Drug data last refreshed 11h ago · AI intelligence enriched 4w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APHEXDA (motixafortide) is a CXCR4 antagonist that mobilizes hematopoietic stem and progenitor cells from bone marrow into peripheral circulation by blocking SDF-1α/CXCL12 binding. It is administered as a subcutaneous powder injection and enables mobilization of stem cells for transplantation with long-term repopulating capacity. The drug was approved in September 2023 and represents a novel mobilization strategy for stem cell harvest.
Peak15.2 years to LOE
Product is in peak commercial phase with 15+ years of patent protection, supporting sustained team investment and career growth opportunities.
Mechanism of Action
C-X-C Motif Chemokine Receptor 4 (CXCR4) and blocks the binding of its cognate ligand, stromal-derived factor-1α (SDF-1α)/C-X-C Motif Chemokine Ligand 12 (CXCL12). SDF-1α and CXCR4 play a role in the trafficking and homing of human hematopoietic stem cells to the marrow compartment. Once in the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (6)
Motixafortide for MRD Sensitization in AML
Started Jul 2026
10 enrolled
Acute Myeloid LeukemiaMeasurable Residual Disease
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
Started Dec 2025
60 enrolled
Multiple Myeloma
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Started Sep 2025
94 enrolled
Multiple Myeloma
A Pharmacodynamic Study of the Apheresis Product of Multiple Myeloma Patients Undergoing Quad-induction Followed by Motixafortide + G-CSF Mobilization
Started Oct 2024
20 enrolled
Multiple Myeloma
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)
Started Jul 2023
10 enrolled
Sickle Cell Disease
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.